Oxford Biodyn Regulatory News (OBD)

17 July 2025

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

GenomeWeb to host joint Agilent/OBD presentation on the EpiSwitch® 3D Genomic Platform and Agilent SureScan Array

Oxford, UK - 17 July 2025 - Oxford Biodynamics (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch 3D genomics platform, is pleased to highlight a webinar, at 6.00 pm BST today, Thursday 17 July, hosted by GenomeWeb, and sponsored by Agilent Technologies (NYSE:A).

The EpiSwitch Array Platform is technology developed by Oxford BioDynamics which leverages Agilent's configurable SureScan microarray to interrogate key elements of 3D genome architecture. These key elements enable the discovery of statistically significant conditional genome interactions specifically associated with diseases. The EpiSwitch platform has demonstrated a path through discovery using Agilent arrays to AI-powered 3D genomics data knowledge, providing disease insights, target identification and translation into actionable clinical tests for early diagnosis, prognosis and response to treatment.

In the webinar, OBD's Chief Scientific Officer, Alexandre Akoulitchev, will present examples of the scale, depth and biological insights that are possible utilising Agilent arrays and OBD's EpiSwitch platform, transforming complex layers of network biology into a clinically actionable, AI-powered system that drives real-world precision medicine. Examples of practical applications will include OBD's reflex test for accurate detection of prostate cancer (EpiSwitch PSE)1,2 and its Multi-Cancer Early Detection (MECD) Specific Canine Blood (EpiSwitch SCB) array test for highly accurate diagnosis of sarcomas, lymphomas and malignant melanoma in dogs3. Valentina Maran, Senior Product Manager at Agilent, will join to discuss Agilent's pivotal role in enabling this innovation.

Webinar objectives:

· Understand 3D genomics as a fundamental biological phenomenon.

· Application of the EpiSwitch Explorer Array: An Agilent-enabled tool for translation of cellular network complexities and development of robust biomarkers.

· Discussion of real-world examples and translation into practice: EpiSwitch PSE and SCB; an accurate clinical prostate cancer detection test and a multi-cancer array-based diagnostic platform.

Register for the event here.

Thomas Guiel, COO of Oxford Biodynamics:

"We have collaborated with Agilent for quite a number of years to develop custom 3D genomics arrays across multiple configurations and species. These arrays have been integral to the development of our EpiSwitch tests and assays, as well as in research initiatives for pharmaceutical companies and other partners.

Our EpiSwitch Explorer Array Kit, which allows life science researchers to simultaneously interrogate almost one million chromosome conformations across the genome, as part of non-biased biomarker discovery and screening, is based on Agilent's SureScan microarray platform, which is available world-wide.

This strategic collaboration has been pivotal in the advancement of our EpiSwitch Platform, supporting high-resolution, rapid, and reproducible detection of disease-specific 3D genomic biomarkers from blood samples. The resulting tests are more accurate, scalable, and practical for routine clinical and research use."

References:

1 Pchejetski, D.; Hunter, E.; Dezfouli, M.; Salter, M.; Powell, R.; Green, J.; Naithani, T.; Koutsothanasi, C.; Alshaker, H.; Jaipuria, J.; et al. Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection. Cancers 2023, 15, 821. https://doi.org/10.3390/cancers15030821

2 Berghausen, J.; Abdo, J.; Mathis, R.; Hunter, E.; Akoulitchev, A.; Pohlman, G.D. EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study. Cancers 2025, 17, 2193. https://doi.org/10.3390/cancers17132193

3 Ewan Hunter, Matthew Salter, Ryan Powell, Ann Dring, Tarun Naithani, Dominik Vugrinec, Kyrylo Shliaiev, Mutaz Issa, Cicely Weston, Abigail Hatton, AbelGebregzabhar, Jayne Green, Anthony Blum, Thomas Guiel, Sara Fritz, Davis Seelig, Jaime F. Modiano, Alexandre Akoulitchev. Whole Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and Validation of EpiSwitch Multi-Choice Array-Based Diagnostic Test. bioRxiv 2024.05.22.595358; doi: https://doi.org/10.1101/2024.05.22.595358

-Ends-

For further information please contact:

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.